GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Other Current Payables

Roquefort Therapeutics (LSE:ROQ) Other Current Payables : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Other Current Payables?

Roquefort Therapeutics's Other Current Payables for the quarter that ended in Dec. 2023 was £0.00 Mil.


Roquefort Therapeutics Other Current Payables Historical Data

The historical data trend for Roquefort Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Other Current Payables Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Other Current Payables
- - -

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23
Other Current Payables 0.01 1.02 - - -

Roquefort Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Roquefort Therapeutics Other Current Payables Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics (LSE:ROQ) Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines